Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04222491 · ClinicalTrials.gov registry record
Food Oral Immunotherapy for Peanut Allergy
A clinical trial, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- 500
- Enrollment target
NCT04222491: Active study, sponsored by Massachusetts General Hospital.
NCT04222491 is a clinical trial that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04222491 is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 500 participants
- Enrollment target
Study Summary
This is an open label observational single center study of clinical food oral immunotherapy outcomes with biomarker samples and participant and/or caregiver-completed questionnaires in participants between 6 months and 65 years of age with IgE-mediated peanut allergy undergoing food oral immunotherapy.
Primary Outcome
Feasibility analysis as assessed by the proportion of participants who tolerate the maintenance dose in a dichotomous manner
Interventions
- DRUG Peanut oral immunotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2020-06-25 |
| Est. Completion | 2026-12 |
What the registry record for NCT04222491 still lists
NCT04222491 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Peanut oral immunotherapy is the first listed.
NCT04222491 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04222491 about?
NCT04222491 is a clinical study titled "Food Oral Immunotherapy for Peanut Allergy". This is an open label observational single center study of clinical food oral immunotherapy outcomes with biomarker samples and participant and/or caregiver-completed questionnaires in participants between 6 months and 65 years of age with IgE-mediated peanut allergy undergoing food oral immunothera...
What is the current status of trial NCT04222491?
This trial is currently active not recruiting. The enrollment target is 500 participants. The study started on 2020-06-25. Estimated completion is 2026-12.
What interventions are being tested in trial NCT04222491?
The interventions under investigation include: Peanut oral immunotherapy (DRUG).
Who is sponsoring clinical trial NCT04222491?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI